MAHONEY DAVID L 4

What Happened
David L. Mahoney, a director of Corcept Therapeutics (CORT), was reported as acquiring a grant of 12,500 derivative shares on May 21, 2026. The filing shows an acquisition price of $0.00 (no cash paid). This was recorded as an award/grant (transaction code A) — not an open-market purchase or sale — and does not indicate any immediate disposition of shares.

Key Details

• Transaction date: 2026-05-21; reported in a Form 4 filed 2026-05-26.
• Transaction type and amount: Award/grant of 12,500 derivative shares at $0.00.
• Vesting: “Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period,” subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in this filing.
• Timeliness: Filed five days after the transaction date (typically Form 4s are due within two business days); this appears to be a late filing.
• Other note: The filing states a power of attorney was used to sign the form.

Context
This is a compensation-related award that vests monthly over 12 months rather than an immediate market purchase or sale. For retail investors, such grants are common as retention incentives and do not by themselves signal a near-term buy or sell by the insider. Because it’s a derivative award with vesting conditions, the economic value to the insider will depend on Corcept’s stock price as vesting occurs.